The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2021 | First results of head-to-head acalabrutinib versus ibrutinib in CLL
John Byrd, MD, Ohio State University, Columbus, OH, outlines results of the head-to-head ELEVATE CLL R/R trial (NCT02477696) of the Bruton’s tyrosine kinase (BTK) inhibitors acalabrutinib versus ibrutinib for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Dr Byrd comments on the significance of this study and gives an overview of the study’s design. Dr Byrd discusses the safety profile that was observed for each of these drugs in this trial, highlighting that atrial fibrillation was more common with ibrutinib therapy than with acalabrutinib. The study reported the same progression-free survival with ibrutinib and acalabrutinib, with overall survival outcomes favoured with acalabrutinib therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
John Byrd, MD, has received honoraria from AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium Therapeutics; has participated in a consultancy or advisory role for Acerta Pharma, Genentech, Pharmacyclics and Jazz Pharmaceuticals; and has received research funding from Acerta Pharma and Pharmacyclics.
